About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 72 record(s)
Req # A-2022-000155
Footnote #37 of the Evaluation of the Health Portfolio Tobacco and Vaping Activities 2016-17 to 2020-21, made public on Health Canada's website on April 26, 2022 makes reference to the following document: "Health Canada (2017). Technical…Organization: Health Canada
July 2022
Req # A-2021-001045
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_03811824, E2B_03841105, E2B_03840754.Organization: Health Canada
July 2022
Req # A-2021-002112
Adverse Drug Reactions (ADRs) for METRONIDAZOLE, METFORMIN HYDROCHLORIDE. Report numbers: E2B_04948923, E2B_04707501.Organization: Health Canada
July 2022
Req # A-2021-002151
Adverse Drug Reaction (ADR) for LEFLUNOMIDE. Report number: E2B_04749239.Organization: Health Canada
July 2022
Req # A-2022-000044
Adverse Drug Reaction (ADR) for Zostavax II. Report number: E2B_02235603.Organization: Health Canada
July 2022
Req # A-2022-000076
Adverse Drug Reaction (ADR) for METFORMIN HYDROCHLORIDE. Report number: E2B_05082566.Organization: Health Canada
July 2022
Req # A-2022-000080
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02647003, E2B_02646771.Organization: Health Canada
July 2022
Req # A-2022-000096
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, FUROSEMIDE DANAZOL. Report numbers: E2B_04983075, E2B_05082215, E2B_05056270.Organization: Health Canada
July 2022
Req # A-2022-000121
Adverse Drug Reactions (ADRs) for BISACODYL, DOCUSATE SODIUM. Report numbers: 000980262, E2B_04987682.Organization: Health Canada
July 2022
Req # A-2022-000148
Adverse Drug Reaction (ADR) for ZOSTAVAX II. Report number: E2B_02575430.Organization: Health Canada
July 2022